Table 3 Treatment changes (%) over first year since initiation of therapy according to baseline OAD*
Overall | Monotherapy | Combination | |||
|---|---|---|---|---|---|
Metformin | Gliclazide | Glimepiride | Metformin & Gliclazide | ||
Discontinuation of index OAD | 31.0 (30.5,31.4) | 29.6 (29.2,30.1) | 39.6 (37.9,41.3) | 33.6 (28.2,39.2) | 51.4 (47.2,55.7) |
Discontinuation of all OAD | 24.6 (24.2,25.0) | 24.0 (23.6,24.5) | 30.8 (29.2,32.4) | 25.2 (20.3,30.5) | 19.7 (16.5,23.3) |
Switch of index OAD | 6.1 (5.9,6.3) | 5.8 (5.6,6.1) | 8.0 (7.1,9.0) | 8.7 (5.8,12.5) | 2.9 (1.6,4.6) |
Augmentation of index OAD | 12.9 (12.6,13.3) | 12.4 (12.1,12.7) | 19.7 (18.3,21.1) | 17.9 (13.6,22.6) | 3.4 (2.1,5.3) |
Started insulin | 2.0 (1.8,2.1) | 1.4 (1.3,1.5) | 7.0 (6.1,7.9) | 5.0 (2.8,8.2) | 6.8 (4.9,9.2) |